Journals Library

An error occurred retrieving content to display, please try again.

Page not found (404)

Sorry - the page you requested could not be found.

Please choose a page from the navigation or try a website search above to find the information you need.

The RCT evidence showed clinical benefits from everolimus and sunitinib in neuroendocrine tumours, while the cost-effectiveness of the drugs ranged from about £20,000 to nearly £200,000 per QALY.

{{author}}{{author}}{{($index < metadata.AuthorsAndEtalArray.length-1) ? ',' : '.'}}

Ruben Mujica-Mota, Jo Varley-Campbell, Irina Tikhonova, Chris Cooper, Ed Griffin, Marcela Haasova, Jaime Peters, Stefano Lucherini, Juan Talens-Bou, Linda Long, David Sherriff, Mark Napier, John Ramage & Martin Hoyle.

Ruben Mujica-Mota 1,*, Jo Varley-Campbell 1, Irina Tikhonova 1, Chris Cooper 1, Ed Griffin 1, Marcela Haasova 1, Jaime Peters 1, Stefano Lucherini 1, Juan Talens-Bou 1, Linda Long 1, David Sherriff 2, Mark Napier 3, John Ramage 4, Martin Hoyle 1

1 Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK
2 Plymouth Oncology Centre, Plymouth Hospitals NHS Trust, Plymouth, UK
3 Exeter Oncology Centre, Royal Devon & Exeter NHS Foundation Trust, Exeter, UK
4 Neuroendocrine Tumour Service, King’s College Hospital NHS Foundation Trust, London, UK
* Corresponding author Email:

Funding: {{metadata.Funding}}

{{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}}{{metadata.DOI}}

Citation: {{author}}{{ (($index < metadata.AuthorsArray.length-1) && ($index <=6)) ? ', ' : '' }}{{(metadata.AuthorsArray.length <= 6) ? '.' : '' }} {{(metadata.AuthorsArray.length > 6) ? 'et al.' : ''}} . {{metadata.JournalShortName}} {{metadata.PublicationDate | date:'yyyy'}};{{metadata.Volume}}({{metadata.Issue}})

Crossmark status check

Report Content

The full text of this issue is available as a PDF document from the Toolkit section on this page.

The full text of this issue is available as a PDF document from the Toolkit section on this page.

If you would like to receive a notification when this project publishes in the NIHR Journals Library, please submit your email address below.


Responses to this report

No responses have been published.


If you would like to submit a response to this publication, please do so using the form below:

Comments submitted to the NIHR Journals Library are electronic letters to the editor. They enable our readers to debate issues raised in research reports published in the Journals Library. We aim to post within 14 working days all responses that contribute substantially to the topic investigated, as determined by the Editors.  Non-relevant comments will be deleted.

Your name and affiliations will be published with your comment.

Once published, you will not have the right to remove or edit your response. The Editors may add, remove, or edit comments at their absolute discretion.

By submitting your response, you are stating that you agree to the terms & conditions